Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takashi Muramatsu is active.

Publication


Featured researches published by Takashi Muramatsu.


Journal of Biological Chemistry | 1999

A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta.

Nobuaki Maeda; Keiko Ichihara-Tanaka; Terutoshi Kimura; Kenji Kadomatsu; Takashi Muramatsu; Masaharu Noda

Midkine is a 13-kDa heparin-binding growth factor with 45% sequence identity to pleiotrophin. Pleiotrophin has been demonstrated to bind to protein-tyrosine phosphatase ζ (PTPζ) with high affinity. In this study, we examined the binding of midkine to PTPζ by solid-phase binding assay. Midkine and pleiotrophin binding to PTPζ were equally inhibited by soluble pleiotrophin and also by some specific glycosaminoglycans. For both bindings, Scatchard analysis revealed low (3.0 nm) and high (0.58 nm) affinity binding sites. These results suggested that PTPζ is a common receptor for midkine and pleiotrophin. Midkine is structurally divided into the N- and C-terminal halves, and the latter exhibited full activity for PTPζ binding and neuronal migration induction. The C-terminal half contains two heparin-binding sites consisting of clusters of basic amino acids, Clusters I and II. A mutation at Arg78 in Cluster I resulted in loss of the high affinity binding and reduced neuronal migration-inducing activity, while mutations at Lys83 and Lys84 in Cluster II showed almost no effect on either activity. Chondroitinase ABC-treated PTPζ exhibited similar low affinity binding both to the native midkine and midkine mutants at Arg78. These results suggested that Arg78 in midkine plays an essential role in high affinity binding to PTPζ by interacting with the chondroitin sulfate portion of this receptor.


Archive | 2000

Methods for detecting early cancer

Takashi Muramatsu; Kohji Okamoto; Shinya Ikematsu; Munehiro Oda; Hideshi Kumai; Sadatoshi Sakuma


Archive | 1998

Treatment of peptic ulcers using midkine (MK) proteins

Masayuki Uchida; Shinya Ikematsu; Minehiko Yokoyama; Akio Yamashita; Hideshi Kumai; Munehiro Oda; Naoki Kato; Sadatoshi Sakuma; Takashi Muramatsu


Archive | 2003

Therapeutic agents for apoptosis-related diseases

Shinya Ikematsu; Yoshihiro Yoshida; Kenji Kadomatsu; Munehiro Oda; Sadatoshi Sakuma; Kin-ya Ashida; Kohsuke Kino; Takashi Muramatsu


Archive | 1999

Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis

Kenji Kadomatsu; Mitsuru Horiba; Takashi Muramatsu; Shinya Ikematsu; Sadatoshi Sakuma


Archive | 1999

Remedies for apoptosis-associated diseases

Takashi Muramatsu; Shinya Ikematsu; Yoshihiro Yoshida; Kenji Kadomatsu; Munehiro Oda; Sadatoshi Sakuma; Kin-ya Ashida; Kohsuke Kino


Archive | 1998

Method for suppressing or treating drug-induced nephropathy

Takashi Muramatsu; Kenji Kadomatsu; Munehiro Oda; Shinya Ikematsu; Sadatoshi Sakuma


Archive | 2002

Agents comprising midkine or its inhibitor as active ingredient

Tohru Takada; Kazuhiro Toriyama; Hisako Muramatsu; Takashi Muramatsu


Archive | 2000

Early cancer tumor marker

Takashi Muramatsu; Kohji Okamoto; Shinya Ikematsu; Munehiro Oda; Hideshi Kumai; Sadatoshi Sakuma


Archive | 2000

Monoclonal antibody against human mk

Shinya Ikematsu; Kenji Kadomatsu; Takashi Muramatsu; Toshiko Muramatsu; Munehiro Oda; Sadatoshi Sakuma; 貞俊 佐久間; 宗宏 小田; 喬 村松; 寿子 村松; 真也 池松; 健治 門松

Collaboration


Dive into the Takashi Muramatsu's collaboration.

Top Co-Authors

Avatar

Kenji Kadomatsu

Graduate University for Advanced Studies

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Itsuo Yokoyama

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge